# Spotlight Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spotlight-therapeutics

- Industry: Biotechnology
- Headquarters: Hayward, US
- Website: www.spotlighttx.com
- Total disclosed funding: $47M
- Latest round: Series B (Dec 10, 2021)
- Investors on record: 5

## About

Spotlight Therapeutics, Inc. is a US-based biotechnology firm focused on developing advanced therapeutic solutions for various diseases through innovative genetic medicine and delivery technologies.Spotlight Therapeutics, Inc. was founded in 2017 and is headquartered in Hayward, US. The company specializes in pioneering biotechnological solutions aimed at enhancing therapeutic delivery methods. It has engaged in five funding deals, with the latest taking place in February 2025, raising USD 66.5 mn from returning investor GV. The company does not have reported subsidiaries or major pivots in its business strategy. CEO Mary Haak-Frendscho leads the firm, which was founded by Jacob Corn.Spotlight Therapeutics, Inc. provides innovative biotechnology products focused on developing genetic medicines. Their platform is designed to improve treatment efficacy and patient outcomes through advanced delivery systems. The company caters to various therapeutic areas, positioning its solutions for diverse healthcare markets, including North America and Europe.Spotlight Therapeutics, Inc. generates revenue through partnerships and potential future product sales following successful development and regulatory approvals. Their focus on innovative delivery technologies is expected to support revenue generation as products move towards market readiness.Spotlight Therapeutics, Inc. plans to leverage the recent funding of USD 66.5 mn to further develop its genetic medicine pipeline, with several new products in the design phase expected to launch in 2026. The company is targeting expansion into additional markets in Europe and Asia, aiming for a broader international footprint by 2027. Recent funding will be instrumental in enhancing research capabilities and facilitating market entry initiatives.

## Funding rounds

- Series B, Dec 10, 2021, $32M — GV, Epiq Capital, Emerson Collective, Magnetic, GordonMD Global Investments
- Series A, Nov 30, 2020, $15M — GV

## Investors

- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Epiq Capital (https://capitalatlas.ai/funds/epiq-capital) — Series B
- Emerson Collective — Series B
- Magnetic (https://capitalatlas.ai/funds/magnetic) — Series B
- GordonMD Global Investments (https://capitalatlas.ai/funds/gordonmd-global-investments) — Series B